Amarin Corp Plc (AMRN)

[jessellivermore]

Raistthemage...

I think Raist has some very good ideas on how we can get out of this "Tiger Trap" and still keep,our skins...Raist like most of the sober contributors on this board is no fan of JT...JT seems...well JT is pretty much just in it for himself...Trying the patent case in the Ninth District was a total blunder and raises questions about Kennedy who lives in San Francisco..putting his own comfort..above the stock holders' interest..

All this is history and we must concentrate on the future...Can Amarin be saved...Can we all get a portion (a big portion) of our losses back..I believe we can...We need a strategy and I like the way Raist is thinking.

The plan would be as follows..We approach TEVA and offer to make them an "authorised Generic"....That means we make Amarin's FDA approved API available to TEVA and essentially go into partnership with them..Amarin still has the suppliers and will be able to provide the same FDA approved Vascepa at a price that Hikma and Reddi will not be able to match..Right now the issue is the R-I indication (the Marine indication is less than ten percent of the Vascepa pie)..And under the terms of Du decision H&R do not have a clear path to the R-I indication...The R-I patents have not been invalidated..

There are several other advantages that the Raistthemage gambit offers..Amarin currently has no face in Europe.. Europe is a big and complicated territory..Amarin has pretty much shown it is not clever enough to navigate big and complicated terrains...TEVA on the other hand has a presence in Europe and knows the territory...Th nice thing about Vascepa is that it is an enormous drug and it is so huge that it can support two families and make them both very rich..Amarin can partner with TEVA and give TEVA a percent of the Vascepa profits for the R-I indication..Terms to be worked out...By partnering with TEVA (an Authorised Generic...in both the USA and Europe..They can essentially essentially make it very difficult for H&R to compete..The drug market always operates off the cheapest alternative..The thing about Vascepa that everyone needs to understand is that Vascepa is a "VOLUME" play..and not a PRICE play..."Fast nickels beat slow dimes"..

":>) JL